FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318092826> ?p ?o ?g. }

• W2318092826 endingPage "330" @default.
• W2318092826 startingPage "329.3" @default.
• W2318092826 abstract "<h3>Objectives</h3> To evaluate the 1 year clinical outcomes of remission steered therapy in early arthritis, initially with methotrexate (MTX) and a tapered high dose of prednisone, in case of remission followed by tapering medication to zero, in case of no remission followed by randomization to two combination therapy strategies. <h3>Methods</h3> IMPROVED is a multicenter clinical trial in 479 patients with early (symptoms <2 years) rheumatoid arthritis (RA 2010 criteria) and 131 patients with undifferentiated arthritis (UA) with a baseline Disease Activity Score (DAS) ≥1.6. All patients started with MTX 25mg/wk and prednisone 60mg/day tapered in 7 weeks to 7.5 mg/day. Patients in early remission (DAS <1.6 at t=4 months) tapered prednisone to zero and when still in remission at t=8 months, also tapered MTX to zero. Patients not in early remission were randomized either to a combination of MTX 25 mg/wk, hydroxychloroquine (HCQ) 400mg/day, sulphasalazine 2000mg/day (SSZ) and prednisone 7.5 mg/day (arm 1) or to adalimumab (ADA) 40mg/2weeks with MTX 25mg/wk (arm 2). If not in remission at t=8 months, patients in arm 1 switched to ADA+MTX and patients in arm 2 increased ADA to 40mg/week. Proportions of remission after one year follow up were compared between the different treatment strategies and between RA and UA patients. <h3>Results</h3> After 4 months 375/610 (61%) patients achieved early remission (mean DAS (SD) 0.94 (0.36)) and 221/610 (36%) did not (mean DAS (SD) 2.45 (0.65), p<0.001). 161/610 patients (26%) were randomized, 83 to arm 1 and 78 to arm 2. In 66/610 (11%) patients the appropriate treatment step was not taken for various reasons. 12 patients were lost to follow up at t=4 months and 34 at t=1 year. At t=4 months, 361/375 (96%) patients in early remission started tapering prednisone. At t=8 months 257/375 (68%) were still in remission on MTX monotherapy and 200/375 (53%) tapered MTX to zero. At t=1 year, 255/375 (68%) were in remission, 135/375 (36%) were in drug free remission. At t=8 months 50/83 (60%) patients in arm 1 did not achieve remission and 31/83 (37%) switched to ADA+MTX. 47/78 (60%) patients in arm 2 did not achieve remission and 27/78 (35%) increased ADA. At t=1 year 21/83 (25%) patients in arm 1 and 32/78 (41%) in arm 2 were in remission (p<0.001). At t=1 year, 326/610 (53%) of the total study population were in remission: 252/479 (53%) RA patients and 70/131 (53%) UA patients. <h3>Conclusions</h3> In patients with early RA or UA, early remission was achieved in 61% after initial treatment with MTX and a tapered high dose of prednisone. After one year of tapering treatment, 68% of those were still in remission and 36% in drug free remission. For those not in early remission, treatment with adalimumab resulted in more remission than a combination of DMARDs with low dose prednisone. Of the total study population 53% were in remission after one year, without a significant difference between early RA and UA patients. <h3>Disclosure of Interest</h3> L. Heimans: None Declared, K. Wevers-de Boer Grant/Research support from: Abbott, K. Visser: None Declared, H. Ronday: None Declared, M. Oosterhout: None Declared, J. Harbers: None Declared, A. Peeters: None Declared, M. Westedt: None Declared, P. de Buck: None Declared, P. de Sonnaville: None Declared, B. Grillet: None Declared, T. Huizinga: None Declared, C. Allaart: None Declared" @default.
• W2318092826 created "2016-06-24" @default.
• W2318092826 creator A5002597067 @default.
• W2318092826 creator A5007724242 @default.
• W2318092826 creator A5007929221 @default.
• W2318092826 creator A5015727845 @default.
• W2318092826 creator A5020569740 @default.
• W2318092826 creator A5023152962 @default.
• W2318092826 creator A5037932695 @default.
• W2318092826 creator A5039811659 @default.
• W2318092826 creator A5040952246 @default.
• W2318092826 creator A5047575658 @default.
• W2318092826 creator A5052842332 @default.
• W2318092826 creator A5060529637 @default.
• W2318092826 creator A5063721236 @default.
• W2318092826 date "2013-06-01" @default.
• W2318092826 modified "2023-09-27" @default.
• W2318092826 title "FRI0061 Remission after one year follow up of the improved-study, a randomized clinical trial aiming at remission in patients with early rheumatoid and undifferentiated arthritis" @default.
• W2318092826 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2518" @default.
• W2318092826 hasPublicationYear "2013" @default.
• W2318092826 type Work @default.
• W2318092826 sameAs 2318092826 @default.
• W2318092826 citedByCount "3" @default.
• W2318092826 countsByYear W23180928262012 @default.
• W2318092826 countsByYear W23180928262013 @default.
• W2318092826 countsByYear W23180928262015 @default.
• W2318092826 crossrefType "journal-article" @default.
• W2318092826 hasAuthorship W2318092826A5002597067 @default.
• W2318092826 hasAuthorship W2318092826A5007724242 @default.
• W2318092826 hasAuthorship W2318092826A5007929221 @default.
• W2318092826 hasAuthorship W2318092826A5015727845 @default.
• W2318092826 hasAuthorship W2318092826A5020569740 @default.
• W2318092826 hasAuthorship W2318092826A5023152962 @default.
• W2318092826 hasAuthorship W2318092826A5037932695 @default.
• W2318092826 hasAuthorship W2318092826A5039811659 @default.
• W2318092826 hasAuthorship W2318092826A5040952246 @default.
• W2318092826 hasAuthorship W2318092826A5047575658 @default.
• W2318092826 hasAuthorship W2318092826A5052842332 @default.
• W2318092826 hasAuthorship W2318092826A5060529637 @default.
• W2318092826 hasAuthorship W2318092826A5063721236 @default.
• W2318092826 hasConcept C126322002 @default.
• W2318092826 hasConcept C141071460 @default.
• W2318092826 hasConcept C142724271 @default.
• W2318092826 hasConcept C168563851 @default.
• W2318092826 hasConcept C198451711 @default.
• W2318092826 hasConcept C204243189 @default.
• W2318092826 hasConcept C204787440 @default.
• W2318092826 hasConcept C2776434150 @default.
• W2318092826 hasConcept C2777077863 @default.
• W2318092826 hasConcept C2777575956 @default.
• W2318092826 hasConcept C2778720950 @default.
• W2318092826 hasConcept C2779123688 @default.
• W2318092826 hasConcept C2779134260 @default.
• W2318092826 hasConcept C2780132546 @default.
• W2318092826 hasConcept C2781059491 @default.
• W2318092826 hasConcept C3008058167 @default.
• W2318092826 hasConcept C524204448 @default.
• W2318092826 hasConcept C71924100 @default.
• W2318092826 hasConcept C90924648 @default.
• W2318092826 hasConceptScore W2318092826C126322002 @default.
• W2318092826 hasConceptScore W2318092826C141071460 @default.
• W2318092826 hasConceptScore W2318092826C142724271 @default.
• W2318092826 hasConceptScore W2318092826C168563851 @default.
• W2318092826 hasConceptScore W2318092826C198451711 @default.
• W2318092826 hasConceptScore W2318092826C204243189 @default.
• W2318092826 hasConceptScore W2318092826C204787440 @default.
• W2318092826 hasConceptScore W2318092826C2776434150 @default.
• W2318092826 hasConceptScore W2318092826C2777077863 @default.
• W2318092826 hasConceptScore W2318092826C2777575956 @default.
• W2318092826 hasConceptScore W2318092826C2778720950 @default.
• W2318092826 hasConceptScore W2318092826C2779123688 @default.
• W2318092826 hasConceptScore W2318092826C2779134260 @default.
• W2318092826 hasConceptScore W2318092826C2780132546 @default.
• W2318092826 hasConceptScore W2318092826C2781059491 @default.
• W2318092826 hasConceptScore W2318092826C3008058167 @default.
• W2318092826 hasConceptScore W2318092826C524204448 @default.
• W2318092826 hasConceptScore W2318092826C71924100 @default.
• W2318092826 hasConceptScore W2318092826C90924648 @default.
• W2318092826 hasIssue "Suppl 3" @default.
• W2318092826 hasLocation W23180928261 @default.
• W2318092826 hasOpenAccess W2318092826 @default.
• W2318092826 hasPrimaryLocation W23180928261 @default.
• W2318092826 hasRelatedWork W202035660 @default.
• W2318092826 hasRelatedWork W2081120248 @default.
• W2318092826 hasRelatedWork W2107294984 @default.
• W2318092826 hasRelatedWork W2275338833 @default.
• W2318092826 hasRelatedWork W2323836956 @default.
• W2318092826 hasRelatedWork W2783320362 @default.
• W2318092826 hasRelatedWork W2884735395 @default.
• W2318092826 hasRelatedWork W4323923081 @default.
• W2318092826 hasRelatedWork W4381571638 @default.
• W2318092826 hasRelatedWork W84416910 @default.
• W2318092826 hasVolume "71" @default.
• W2318092826 isParatext "false" @default.
• W2318092826 isRetracted "false" @default.
• W2318092826 magId "2318092826" @default.
• W2318092826 workType "article" @default.